{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:32:59Z","timestamp":1772119979621,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03567-5","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T04:02:43Z","timestamp":1700107363000},"page":"459-465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Renal safety of zoledronic acid in patients with osteoporosis: a retrospective study"],"prefix":"10.1007","volume":"83","author":[{"given":"Yanhua","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Decai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1217-1387","authenticated-orcid":false,"given":"Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"3567_CR1","first-page":"413","volume":"10","author":"Chinese Society of Osteoporosis and Bone Mineral Research.","year":"2017","unstructured":"Chinese Society of Osteoporosis and Bone Mineral Research., Guidelines for the diagnosis and management of primary osteoporosis. Chin. J. Osteoporos. Bone Min. Res. 10, 413\u2013444 (2017)","journal-title":"Chin. J. Osteoporos. Bone Min. Res."},{"key":"3567_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med 356, 1809\u201322 (2007). https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N. Engl. J. Med"},{"key":"3567_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jama.2020.2923","volume":"325","author":"KE: Ensrud","year":"2021","unstructured":"K.E: Ensrud, Bisphosphonates for postmenopausal osteoporosis. JAMA 325, 96 (2021). https:\/\/doi.org\/10.1001\/jama.2020.2923","journal-title":"JAMA"},{"key":"3567_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/gl-2020-0524suppl","volume":"26","author":"PM Camacho","year":"2020","unstructured":"P.M. Camacho, S.M. Petak, N. Binkley, D.L. Diab, L.S. Eldeiry, A. Farooki et al. American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr. Pract. 26, 1\u201346 (2020). https:\/\/doi.org\/10.4158\/gl-2020-0524suppl","journal-title":"Endocr. Pract."},{"key":"3567_CR5","first-page":"381","volume":"13","author":"Chinese Society of Osteoporosis and Bone Mineral Research.","year":"2020","unstructured":"Chinese Society of Osteoporosis and Bone Mineral Research., Guidelines for the diagnosis and management of male osteoporosis. Chin. J. Osteoporos. Bone Min. Res. 13, 381\u2013395 (2020)","journal-title":"Chin. J. Osteoporos. Bone Min. Res."},{"key":"3567_CR6","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","volume":"349","author":"JT Chang","year":"2003","unstructured":"J.T. Chang, L. Green, J: Beitz, Renal failure with the use of zoledronic acid. N. Engl. J. Med. 349, 1676\u20131679 (2003). https:\/\/doi.org\/10.1056\/NEJM200310233491721","journal-title":"N. Engl. J. Med."},{"key":"3567_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.phrs.2015.04.016","volume":"99","author":"R Bergner","year":"2015","unstructured":"R. Bergner, B. Siegrist, N. Gretz, G. Pohlmeyer-Esch, B. Kranzlin, Nephrotoxicity of ibandronate and zoledronate in wistar rats with normal renal function and after unilateral nephrectomy. Pharm. Res. 99, 16\u201322 (2015). https:\/\/doi.org\/10.1016\/j.phrs.2015.04.016","journal-title":"Pharm. Res."},{"key":"3567_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/cncr.22504","volume":"109","author":"WK Oh","year":"2007","unstructured":"W.K. Oh, K. Proctor, M. Nakabayashi, C. Evan, L.K. Tormey, T. Daskivich et al. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 109, 1090\u20131096 (2007). https:\/\/doi.org\/10.1002\/cncr.22504","journal-title":"Cancer"},{"key":"3567_CR9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5414\/CP201823","volume":"51","author":"YJ Cha","year":"2013","unstructured":"Y.J. Cha, Y.J. Lee, Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid. Int. J. Clin. Pharm. Ther. 51, 274\u2013282 (2013). https:\/\/doi.org\/10.5414\/CP201823","journal-title":"Int. J. Clin. Pharm. Ther."},{"key":"3567_CR10","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1345\/aph.1E589","volume":"39","author":"A Munier","year":"2005","unstructured":"A. Munier, V. Gras, M. Andrejak, N. Bernard, M.J. Jean-Pastor, S. Gautier et al. Zoledronic acid and renal toxicity: data from French adverse effect reporting database. Ann. Pharmacother. 39, 1194\u20131197 (2005). https:\/\/doi.org\/10.1345\/aph.1E589","journal-title":"Ann. Pharmacother."},{"key":"3567_CR11","doi-asserted-by":"publisher","first-page":"e20831","DOI":"10.1097\/MD.0000000000020831","volume":"99","author":"X Dai","year":"2020","unstructured":"X. Dai, Y. Deng, Y. Luo, J. Xie, H. Ma, Effect of different hydration doses on renal function in patients with primary osteoporosis treated with zoledronic acid: a hospital-based retrospective cohort study. Medicine 99, e20831 (2020). https:\/\/doi.org\/10.1097\/MD.0000000000020831","journal-title":"Medicine"},{"key":"3567_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ki.2008.193","volume":"74","author":"S Boonen","year":"2008","unstructured":"S. Boonen, D.E. Sellmeyer, K. Lippuner, A. Orlov-Morozov, K. Abrams, P. Mesenbrink et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 74, 641\u2013648 (2008). https:\/\/doi.org\/10.1038\/ki.2008.193","journal-title":"Kidney Int."},{"key":"3567_CR13","first-page":"733","volume":"25","author":"The committee for the China guideline for the diagnosis criteria of osteoporosis with quantitative computed tomography.","year":"2019","unstructured":"The committee for the China guideline for the diagnosis criteria of osteoporosis with quantitative computed tomography., The China guideline for the diagnosis criteria of osteoporosis with quantitative computed tomography (QCT) (2018). Chin. J. Osteoporos. 25, 733\u2013737 (2019)","journal-title":"Chin. J. Osteoporos."},{"key":"3567_CR14","unstructured":"American College of Radiology.: ACR-SPR-SSR practice guideline for the performance of quantitative computed tomography (QCT) bone densitometry [EB\/OL]. (2014-06-16) [2019-02-28]. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/Practice-Parameters\/QCT.pdf."},{"key":"3567_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jocd.2007.12.010","volume":"11","author":"K Engelke","year":"2008","unstructured":"K. Engelke, J.E. Adams, G. Armbrecht, P. Augat, C.E. Bogado, M.L. Bouxsein et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J. Clin. Densitom. 11, 123\u2013162 (2008). https:\/\/doi.org\/10.1016\/j.jocd.2007.12.010","journal-title":"J. Clin. Densitom."},{"key":"3567_CR16","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/ndt\/gfq535","volume":"26","author":"H Afghahi","year":"2011","unstructured":"H. Afghahi, J. Cederholm, B. Eliasson, B. Zethelius, S. Gudbj\u00f6rnsdottir, H. Hadimeri et al. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes-the Swedish National Diabetes Register (NDR). Nephrol. Dial. Transpl. 26, 1236\u20131243 (2011). https:\/\/doi.org\/10.1093\/ndt\/gfq535","journal-title":"Nephrol. Dial. Transpl."},{"key":"3567_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/iju.14205","volume":"27","author":"Y Nakamura","year":"2020","unstructured":"Y. Nakamura, M. Yokoyama, S. Yoshida, H. Tanaka, T. Kijima, J. Ishioka et al. Postoperative renal impairment and longitudinal change in renal function after adrenalectomy in patients with Cushing\u2019s syndrome. Int. J. Urol. 27, 395\u2013400 (2020). https:\/\/doi.org\/10.1111\/iju.14205","journal-title":"Int. J. Urol."},{"key":"3567_CR18","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"M. Charlson, T.P. Szatrowski, J. Peterson, J. Gold, Validation of a combined comorbidity index. J. Clin. Epidemiol. 47, 1245\u20131251 (1994). https:\/\/doi.org\/10.1016\/0895-4356(94)90129-5","journal-title":"J. Clin. Epidemiol."},{"key":"3567_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/imj.14398","volume":"50","author":"NW Setter","year":"2020","unstructured":"N.W. Setter, M.L. Peres, B.M.M. de Almeida, R.R. Petterle, S.M. Raboni, Charlson comorbidity index scores and in-hospital prognosis of patients with severe acute respiratory infections. Intern. Med. J. 50, 691\u2013697 (2020). https:\/\/doi.org\/10.1111\/imj.14398","journal-title":"Intern. Med. J."},{"key":"3567_CR20","first-page":"115","volume":"11","author":"S Talib","year":"2017","unstructured":"S. Talib, F. Sharif, S. Manzoor, S. Yaqub, W. Kashif, Charlson comorbidity index for prediction of outcome of acute kidney injury in critically ill patients. Iran. J. Kidney Dis. 11, 115\u2013123 (2017)","journal-title":"Iran. J. Kidney Dis."},{"key":"3567_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"P.M. Camacho, S.M. Petak, N. Binkley et al. American Association Of Clinical Endocrinologists\/American College Of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr. Pract. 26, 1\u201346 (2020). https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr. Pract."},{"key":"3567_CR22","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"L.A. Inker, N.D. Eneanya, J. Coresh, H. Tighiouart, D. Wang, Y. Sang et al. Chronic kidney disease epidemiology collaboration. new creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737\u20131749 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2102953","journal-title":"N. Engl. J. Med."},{"key":"3567_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.lfs.2018.04.059","volume":"203","author":"S Singireesu","year":"2018","unstructured":"S. Singireesu, S.K. Mondal, S. Yerramsetty, S: Misra, Zoledronic acid induces micronuclei formation, mitochondrial-mediated apoptosis and cytostasis in kidney cells. Life Sci. 203, 305\u2013314 (2018). https:\/\/doi.org\/10.1016\/j.lfs.2018.04.059","journal-title":"Life Sci."},{"key":"3567_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/s0140-6736(83)92434-0","volume":"1","author":"JA Kanis","year":"1983","unstructured":"J.A. Kanis, C.J. Preston, A.J. Yates, R.C. Percival, K.I. Mundy, R.G. Russell, Effects of intravenous diphosphonates on renal function. Lancet 1, 1328 (1983). https:\/\/doi.org\/10.1016\/s0140-6736(83)92434-0","journal-title":"Lancet"},{"key":"3567_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1615\/jenvironpatholtoxicoloncol.2015012424","volume":"34","author":"I Sehitoglu","year":"2015","unstructured":"I. Sehitoglu, L. Tumkaya, R. Bedir, Y. Kalkan, M.C. Cure, A.F. Yucel et al. Zoledronic acid aggravates kidney damage during ischemia reperfusion injury in rat. J. Environ. Pathol. Toxicol. Oncol. 34, 53\u201361 (2015). https:\/\/doi.org\/10.1615\/jenvironpatholtoxicoloncol.2015012424","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"key":"3567_CR26","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00198-022-06499-4","volume":"33","author":"CW Fixen","year":"2022","unstructured":"C.W. Fixen, D.R. Fixen, Renal safety of zoledronic acid for osteoporosis in adults 75 years and older. Osteoporos. Int 33, 2417\u20132422 (2022). https:\/\/doi.org\/10.1007\/s00198-022-06499-4","journal-title":"Osteoporos. Int"},{"key":"3567_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6904-8-2","volume":"8","author":"A Spencer","year":"2008","unstructured":"A. Spencer, A. Roberts, N. Kennedy, C. Ravera, S. Cremers, S. Bilic et al. Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clin. Pharmacol. 8, 2 (2008). https:\/\/doi.org\/10.1186\/1472-6904-8-2","journal-title":"BMC Clin. Pharmacol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03567-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03567-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03567-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T03:21:27Z","timestamp":1707276087000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03567-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["3567"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03567-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3103523\/v1","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"assertion":[{"value":"24 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies involving human participants were reviewed and approved by the Medical Ethics Committee of West China Hospital of Sichuan University. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}